Gene therapy developers are striving to platform their process development to more quickly and cost-effectively bring their drugs to market, meaning optimizing upstream process development
UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europ
Today saw the debut of a new UK-based biotech, called AlveoGene, which has been formed to develop therapies based on a lentiviral vector platform used to deliver gene ther
Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer
CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the
Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a